Agenus announces 'promising' Prophage G-200 Phase 2 results Agenus announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as "exciting" and a "very promising therapy" in an editorial published in Neuro-Oncology. The results of Agenusí Prophage vaccine Phase 2 study, published last month in Neuro-Oncology, demonstrated that more than 90% of the patients treated with the vaccine candidate were alive at six months. The median overall survival in these patients was approximately 11 months. The results of the Phase 2 trial have garnered the support of the National Cancer Institute. The study is actively enrolling and will offer the opportunity to provide important data to validate assessments of biomarkers and imaging criteria.